|
Report Date : |
19.06.2013 |
IDENTIFICATION DETAILS
|
Name : |
LIPOID AG |
|
|
|
|
Registered Office : |
Sennweidstrasse 44 6312 Steinhausen/ZG |
|
|
|
|
Country : |
Switzerland |
|
|
|
|
Date of Incorporation : |
1977 |
|
|
|
|
Com. Reg. No.: |
170.3.020.351-7 / 363451 |
|
|
|
|
Legal Form : |
Company limited by shares |
|
|
|
|
Line of Business : |
The Subject is a manufacturer of lecithin fractions and phospholipids of plant origin, egg lecithin fractions, hydrogenated lecithin fractions and synthetic phospholipids for the pharmaceutical industry, the cosmetic industry and the dietetics Industry. Brands: LIPOID, PHOSPHOLIPON®, PHOSAL®, PhytoSolve®, SOLUTHIN®, Ultraspheres®. |
|
|
|
|
No. of Employees : |
15 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Switzerland/CH |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
SWITZERLAND - ECONOMIC OVERVIEW
Switzerland is a peaceful, prosperous, and modern market economy
with low unemployment, a highly skilled labor force, and a per capita GDP among
the highest in the world. Switzerland''s economy benefits from a highly
developed service sector, led by financial services, and a manufacturing
industry that specializes in high-technology, knowledge-based production. Its
economic and political stability, transparent legal system, exceptional
infrastructure, efficient capital markets, and low corporate tax rates also
make Switzerland one of the world''s most competitive economies. The Swiss have
brought their economic practices largely into conformity with the EU''s to
enhance their international competitiveness, but some trade protectionism
remains, particularly for its small agricultural sector. The fate of the Swiss
economy is tightly linked to that of its neighbors in the euro zone, which
purchases half of all Swiss exports. The global financial crisis of 2008 and
resulting economic downturn in 2009 stalled export demand and put Switzerland
in a recession. The Swiss National Bank (SNB) during this period effectively
implemented a zero-interest rate policy to boost the economy as well as prevent
appreciation of the franc, and Switzerland''s economy recovered in 2010 with
3.0% growth. The sovereign debt crises currently unfolding in neighboring
euro-zone countries pose a significant risk to Switzerland''s financial
stability and are driving up demand for the Swiss franc by investors seeking a
safe-haven currency. The independent SNB has upheld its zero-interest rate policy
and conducted major market interventions to prevent further appreciation of the
Swiss franc, but parliamentarians have urged it to do more to weaken the
currency. The franc''s strength has made Swiss exports less competitive and
weakened the country''s growth outlook; GDP growth fell to 1.9% in 2011 and
0.8% in 2012. Switzerland has also come under increasing pressure from
individual neighboring countries, the EU, the US, and international
institutions to reform its banking secrecy laws. Consequently, the government
agreed to conform to OECD regulations on administrative assistance in tax
matters, including tax evasion. The government has renegotiated its double
taxation agreements with numerous countries, including the US, to incorporate
the OECD standard, and is considering the possibility of imposing taxes on bank
deposits held by foreigners. These steps will have a lasting impact on
Switzerland''s long history of bank secrecy.
|
Source
: CIA |
LIPOID AG
Operating address:
Sennweidstrasse 44
6312 Steinhausen/ZG
Switzerland/CH
Telephone: 041 7417408
Fax: 041 7486389
Web site: http://www.lipoid.com
E-mail: info@lipoid.com
VAT-No.: CHE108424574
Established: 1977
Line
of Business: Pharmaceutics,
Chemicals
Industry
Division: Manufacturing
Industry-code (NACE): 2110 Manufacture of basic pharmaceutical
products
2059 Manufacture of other chemical products
n.e.c.
Import/Export: Export
Quality
certification: ISO 9001:2008
Banks: unknown
Coverage: Company
Figures: approximately
Employees: 15
The company is a manufacturer of lecithin fractions and phospholipids of plant origin, egg lecithin fractions, hydrogenated lecithin fractions and synthetic phospholipids for the pharmaceutical industry, the cosmetic industry and the dietetics Industry. Brands: LIPOID, PHOSPHOLIPON®, PHOSAL®, PhytoSolve®, SOLUTHIN®, Ultraspheres®.
Information on property ownership was not available.
Company
No: 170.3.020.351-7 / 363451
Legal
form: Company limited by
shares
Registration: 27.09.1995
Legal
status: active
Responsible
Register: Handelsregister des Kantons
Zug
History: Date of Statutes:
29.06.2010
Date of
Statutes: 23.04.1997
Date of
Incorporation Statutes: 26.09.1995
Entry Deleted Name
27.09.1995 Lipoid
AG
Entry Deleted Legal domicile
06.07.2010 Steinhausen,
Switzerland
27.09.1995 06.07.2010 Cham, Switzerland
Entry Deleted Address
06.07.2010 Sennweidstrasse
44, 6312 Steinhausen/ZG, Switzerland/CH
27.09.1995 06.07.2010 Alte Steinhauserstrasse 19, 6330 Cham,
Switzerland/CH
Entry Deleted Capital
30.04.1997 Share
Capital CHF 500,000, paidup CHF 500,000
27.09.1995 30.04.1997 Share Capital CHF 100,000, paidup CHF 100,000
Entry Deleted Capital Structure
30.04.1997 1,000
Registered shares with restricted transferability of CHF 500,--
27.09.1995 30.04.1997 200 Registered shares with restricted
transferability of CHF 500,--
Entry Deleted Activity (original Language)
27.09.1995 Vertrieb
von Zusatzstoffen für die Lebensmittel-, Kosmetik- und Pharma-Industrie; kann
alle Geschäfte des Immobilienverkehrs vornehmen sowie Beteiligungen an anderen
Gesellschaften erwerben, verwalten oder finanzieren.
Entry Deleted Remarks (original Language)
06.07.2010 Shares:
Die Übertragbarkeit der Namenaktien ist nach Massgabe der Statuten beschränkt.
06.07.2010 Reports:
Die Mitteilungen an die Aktionäre erfolgen durch Publikation im SHAB oder,
sofern die Namen und Adressen sämtlicher Aktionäre bekannt sind, durch
eingeschriebenen Brief.
27.09.1995 Publishing
authority: SHAB.
Title Name
President Dr. Herbert
Rebmann, Origin: Germany, Residential address: Neustadt, Germany, single
signature, Registered since: 27.09.1995
Director Hans von Flüe,
Origin: Sachseln, Switzerland, Residential address: Unterägeri, Switzerland,
single signature, Registered since: 27.09.1995
Director Hans-Peter
von Flüe, Origin: Sachseln, Switzerland, Residential address: Unterägeri,
Switzerland, single signature, Registered since: 27.09.1995
Director Dr. Jürgen
Zirkel, Origin: Germany, Residential address: Mutterstadt, Germany, single
signature, Registered since: 16.02.2006
Title Name
Member
with procuration Dr. Frank
Schubert, Origin: Germany, Residential address: Zug, Switzerland, joint power
of attorney of two, Registered since: 15.12.2010
Title Name
Auditor A.
Emmenegger AG, Residential address: Zug, Switzerland, Id: CH-170.3.007.259-6,
Registered since: 27.09.1995
No.
of Owner/-s: 1
Owner: The company is foreign
owned.
Class: 100%
Name: Lipoid GmbH
City/Country: Ludwigshafen, Germany/DE
Interest: 100,00% voting right,
100,00% capital interest
It is believed that the company has no investments.
Control date Year No. Amount CHF Status
24.06.2011 2011 0
24.06.2011 2010 0
24.06.2011 2009 0
An updated legal action check is only
available against proof of interest. e.g. a copy of an enquiry letter, and
order or invoice relating to the subject company.
Financial
Statements: The company does not
disclose any financial statements. Third parties are not permitted any insight
into the financial affairs. It is therefore difficult to make a proper
assessment of the actual situation.
Financial
Situation: The financial situation
is in order.
Payment
experiences: Financial obligations are
met in an orderly manner.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.58.45 |
|
|
1 |
Rs.91.60 |
|
Euro |
1 |
Rs.77.91 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any risk
and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its
officials.